Randomized controlled trials and assessment of drug safety

Drug Safety

Volumn 31, Issue 12, 2008, Pages 1057-1061

  Clark, David W J ^a   Coulter, David M ^b   Besag, Frank M C ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b Twinwoods Health Resource Centre ^*

Author keywords

Clinical trial design; Pharmacovigilance; Randomised controlled trials

Indexed keywords

CAPTOPRIL; ENALAPRIL; ETIRACETAM; FELBAMATE; FENOTEROL; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PRACTOLOL; TIAGABINE; TOPIRAMATE; VIGABATRIN;

APLASTIC ANEMIA; CLINICAL RESEARCH; COUGHING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG USE; DRY EYE; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HUMAN; LIVER TOXICITY; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RASH; REGISTER; RISK ASSESSMENT; UNITED STATES; VISUAL FIELD DEFECT;

DRUGS, INVESTIGATIONAL; HUMANS; PRODUCT SURVEILLANCE, POSTMARKETING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 56749181510     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/0002018-200831120-00002     Document Type: Editorial

References (17)

1. Wood AJJ, Stein CM, Woosley R. Making medicines safer: the need for an independent drug safety board. N Engl J Med 1998; 339: 1851-4
2. Drazen JM, D'Agostino RB, Ware JH, et al. Ezetimibe and cancer: an uncertain association. N Engl J Med 2008; 359 (13): 1398-9
3. Edwards IR. Controlled trials and risk of harm. Drug Saf 2008; 31 (11): 961-3
4. Ropp KL. MedWatch, January 1995 [online]. Available from URL: http://www.fda.gov/FDAC/special/newdrug/medwatch.html [Accessed 2008 Oct 12]
5. French J, Smith M, Faught E, et al. Practice advisory: the use of felbamate in the treatment of patients with intractable epilepsy. Report of the Quality Standards Subcommittee of the American Academy of Neurology and The American Epilepsy Society. Neurology 1999; 52: 1540-5
6. Coulter DM, Edwards IR. Cough associated with captopril and enalapril. BMJ 1987; 294: 1521-3
7. Skegg DCG, Doll R. Frequency of eye complaints and rashes among patients receiving practolol and propranolol. Lancet 1977; ii: 475-8
8. Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. BMJ 1997; 314 (7075): 180-1
9. Wild JM, Martinez C, Reinshagen TG, et al. Characteristics of a unique visual field defect attributed to vigabatrin. Epilepsia 1999; 40 (12): 1784-94
10. Ackers R, Murray ML, Besag FMC, et al. Prioritizing children's medicines for research: a pharmacoepidemiological study of antiepileptic drugs. Br J Clin Pharmacol 2007; 63 (6): 689-97
11. Stricker BH, Psaty BM. Detection, verification, and quantification of adverse drug reactions. BMJ 2004; 329: 44-7
12. Bate A, Lindquist M, Edwards IR, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 1998; 54: 315-21
13. Mann RD. Prescription-event monitoring: recent progress and future horizons. Br J Clin Pharmacol 1998; 46 (3): 195-201
14. Coulter DM. The New Zealand Intensive Medicines Monitoring Programme in pro-active surveillance. Pharmacoepidemiol Drug Saf 2000; 9: 273-80
15. Coulter DM. PEM in New Zealand. In: Mann R, Andrews E, editors. Pharmacovigilance. Chichester: John Wiley & Sons, 2002: 345-62
16. FDA seeks nominations for Reagan-Udall Foundation: foundation part of new FDA law. FDA News 2007 Oct 4 [online]. Available from URL: http://www.fda.gov/ bbs/topics/NEWS/2007/NEW01720.html [Accessed 2008 Oct 22]
17. Psaty BM, Vandenbroucke JP. Opportunities for enhancing the FDA guidance on pharmacovigilance. JAMA 2008; 300 (8): 952-4